Noa Biran, MD

Noa Biran, MD, addresses unmet needs in relapsed/refractory multiple myeloma, focusing on reducing treatment burden and exploring fixed-duration therapies post-transplant, and highlights potential consolidation approaches with CAR-T cells or novel agents.

Noa Biran, MD, discusses the potential sequencing of selinexor with newer B-cell maturation antigen (BCMA)-directed therapies like CAR-T cells and bispecific antibodies, and explores optimizing treatment sequences to maximize efficacy, minimize resistance, and manage toxicity profiles.

Nora Biran, MD, and David Siegel, MD, offer closing remarks on the MM treatment landscape.

Myeloma experts share their thoughts on the future of multiple myeloma treatment.

Experts on multiple myeloma compare their treatment sequencing strategies.

Noa Biran, MD, offers insights on ongoing research with bispecific antibodies in multiple myeloma.

A comprehensive discussion on bispecific antibodies and T-cell engagers in the treatment of multiple myeloma.

Myeloma experts give an overview of allogeneic CAR T-cell therapy and other technology advances in MM.

Noa Biran, MD, and David Siegel, MD, discuss how CAR T-cell availability has impacted the field of multiple myeloma.

Experts on multiple myeloma discuss available BCMA-targeted CAR T-cell therapies and the KarMMa and CARTITUDE-1 clinical trials.

Noa Biran, MD, and David Siegel, MD, review the shifting treatment paradigms in multiple myeloma (MM).